Target Drug Exposure Attainment in Children: How to Get from Better to Best

[1]  S. D. de Wildt,et al.  External Validation of Model-Based Dosing Guidelines for Vancomycin, Gentamicin, and Tobramycin in Critically Ill Neonates and Children: A Pragmatic Two-Center Study , 2020, Pediatric Drugs.

[2]  Julia E. Vogt,et al.  Pharmacometrics and Machine Learning Partner to Advance Clinical Data Analysis , 2020, Clinical pharmacology and therapeutics.

[3]  Anne Smits,et al.  Pharmacokinetic modelling and Bayesian estimation-assisted decision tools to optimize vancomycin dosage in neonates: only one piece of the puzzle , 2019, Expert opinion on drug metabolism & toxicology.

[4]  C. Staatz,et al.  An evaluation of the user-friendliness of Bayesian Forecasting programs in a clinical setting. , 2019, British journal of clinical pharmacology.

[5]  A. Smits,et al.  Larger Dose Reductions of Vancomycin Required in Neonates with Patent Ductus Arteriosus Receiving Indomethacin versus Ibuprofen , 2019, Antimicrobial Agents and Chemotherapy.

[6]  S. Goswami,et al.  Individualized Empiric Vancomycin Dosing in Neonates Using a Model-Based Approach. , 2019, Journal of the Pediatric Infectious Diseases Society.

[7]  L. Lesko,et al.  Model‐Informed Precision Dosing at the Bedside: Scientific Challenges and Opportunities , 2018, CPT: pharmacometrics & systems pharmacology.

[8]  G. Kearns,et al.  Developmental Changes in Pharmacokinetics and Pharmacodynamics , 2018, Journal of clinical pharmacology.

[9]  M. H. Ensom,et al.  The Relationship Between Vancomycin Trough Concentrations and AUC/MIC Ratios in Pediatric Patients: A Qualitative Systematic Review , 2018, Pediatric Drugs.

[10]  J. N. van den Anker,et al.  Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling , 2015, Antimicrobial Agents and Chemotherapy.

[11]  Johan W Mouton,et al.  Novel model-based dosing guidelines for gentamicin and tobramycin in preterm and term neonates. , 2015, The Journal of antimicrobial chemotherapy.

[12]  J. Anker,et al.  Letter to the editor (multiple letters) , 2003 .

[13]  F. Nieman,et al.  Population Pharmacokinetics and Relationship Between Demographic and Clinical Variables and Pharmacokinetics of Gentamicin in Neonates , 2002, Therapeutic drug monitoring.

[14]  R. Schoemaker,et al.  Vancomycin population pharmacokinetics in neonates , 2000, Clinical pharmacology and therapeutics.

[15]  R. Schoemaker,et al.  Tobramycin population pharmacokinetics in neonates * , 1997 .

[16]  J. N. van den Anker,et al.  Thoughts on "Population pharmacokinetics and relationship between demographic and clinical variables and pharmacokinetics of gentamicin in neonates". , 2003, Therapeutic Drug Monitoring.

[17]  S. Kaplan,et al.  Vancomycin pharmacokinetics in premature infants. , 1985, Pediatric pharmacology.